United States
Search    
Include All CSL Behring Country Sites

AFSTYLA ®

Antihemophilic Factor (Recombinant), Single Chain
Full Prescribing Information for AFSTYLA®        Important Safety Information

AFSTYLA is a recombinant, antihemophilic factor indicated in adults and children with hemophilia A (congenital Factor VIII deficiency) for:

  • On-demand treatment and control of bleeding episodes,
  • Routine prophylaxis to reduce the frequency of bleeding episodes,
  • Perioperative management of bleeding.

Visit www.afstyla.com to learn more.

Diagnostic Codes (ICD-10-CM)

Billing Codes (HCPCS, NDC, CPT)

Medicare Part B ASP Pricing Limits

Authorized Distributors

Important Safety Information for AFSTYLA

AFSTYLA®, Antihemophilic Factor (Recombinant), Single Chain, is contraindicated in patients who have had life-threatening hypersensitivity reactions to AFSTYLA or its excipients, or to hamster proteins.

AFSTYLA is for intravenous use only. AFSTYLA can be self-administered or administered by a caregiver with training and approval from a healthcare provider or hemophilia treatment center. Higher and/or more frequent dosing may be needed for patients under 12 years of age.

Hypersensitivity reactions, including anaphylaxis, are possible. Advise patients to immediately report symptoms of a hypersensitivity reaction. If symptoms occur, discontinue AFSTYLA and administer appropriate treatment.

Development of Factor VIII (FVIII) neutralizing antibodies (inhibitors) can occur. If expected FVIII activity levels are not attained or bleeding is not controlled with appropriate dose, perform an assay to measure FVIII inhibitor concentration.

Monitor plasma FVIII activity using a chromogenic assay or one-stage clotting assay. If one-stage clotting assay is used, multiply result by a conversion factor of 2 to determine FVIII activity level.

The most common adverse reactions reported in clinical trials (>0.5%) were dizziness and hypersensitivity.

Indications for AFSTYLA

AFSTYLA is indicated in adults and children with hemophilia A (congenital Factor VIII deficiency) for:

  • On-demand treatment and control of bleeding episodes
  • Routine prophylaxis to reduce frequency of bleeding episodes
  • Perioperative management of bleeding

AFSTYLA is not indicated for the treatment of von Willebrand disease.

Please see full prescribing information for AFSTYLA.


CRP16-05-0001 05/2016
© 2017 CSL Behring